SABINI, ELENA
 Distribuzione geografica
Continente #
NA - Nord America 1.000
EU - Europa 611
AS - Asia 146
AF - Africa 35
SA - Sud America 5
OC - Oceania 2
Totale 1.799
Nazione #
US - Stati Uniti d'America 981
SE - Svezia 254
DE - Germania 104
IT - Italia 94
CN - Cina 61
BG - Bulgaria 57
SG - Singapore 37
GB - Regno Unito 34
AT - Austria 20
CA - Canada 18
CI - Costa d'Avorio 18
FR - Francia 18
SN - Senegal 17
VN - Vietnam 16
IN - India 15
RU - Federazione Russa 12
TR - Turchia 9
UA - Ucraina 8
HK - Hong Kong 6
BR - Brasile 4
BE - Belgio 3
FI - Finlandia 3
AU - Australia 2
NL - Olanda 2
CL - Cile 1
HR - Croazia 1
IE - Irlanda 1
JP - Giappone 1
PA - Panama 1
PH - Filippine 1
Totale 1.799
Città #
Woodbridge 152
Fairfield 135
Houston 96
Chandler 93
Seattle 67
Ashburn 58
Sofia 57
Wilmington 49
Ann Arbor 47
Cambridge 37
New York 30
Serra 27
Beijing 22
Vienna 20
Princeton 19
Abidjan 18
Boardman 18
Ottawa 18
Bremen 17
Dakar 17
Frankfurt am Main 17
Lawrence 17
London 16
Medford 16
Florence 13
Pisa 12
Des Moines 11
Singapore 11
Dearborn 10
Dong Ket 9
Marseille 8
Ogden 6
Izmir 5
San Diego 5
Boulder 4
Hong Kong 4
Nanchang 4
Nanjing 4
Ossé 4
Tianjin 4
Aosta 3
Brussels 3
Hebei 3
Jiaxing 3
Lancaster 3
Manchester 3
Ningbo 3
Palermo 3
Pesqueira 3
Changsha 2
Chengdu 2
Chicago 2
Da Nang 2
Dallas 2
Kent 2
Milan 2
Munich 2
Shenyang 2
Siena 2
Vertemate con Minoprio 2
Baotou 1
Canberra 1
Capannori 1
Central 1
Chelmsford 1
Dublin 1
Harran 1
Highland 1
Istanbul 1
Kunming 1
Le Casine-Perignano-Spinelli 1
Los Angeles 1
Manila 1
Mascali 1
Melbourne 1
Norwalk 1
Panama City 1
Pune 1
Rome 1
San Francisco 1
Santa Clara 1
Santiago 1
Shanghai 1
Shaoxing 1
Terni 1
Vicopisano 1
Volterra 1
Wenzhou 1
Zagreb 1
Totale 1.255
Nome #
Natural history of graves’ orbitopathy after treatment 168
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 159
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 143
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 138
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 118
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 113
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY 111
Occurrence of Graves’ Orbitopathy and of Graves’ hyperthyroidism after a trauma to the eye 104
A case of drug-induced Graves’ Orbitopathy after combination therapy with Tremelimumab and Durvalumab 101
Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question 99
null 93
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study 93
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 85
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 75
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 72
Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot study 72
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 66
Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy 35
Totale 1.845
Categoria #
all - tutte 5.579
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.579


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020344 0 0 32 25 55 46 42 33 34 26 43 8
2020/2021107 9 8 9 13 9 4 4 9 8 11 6 17
2021/2022327 0 3 2 44 87 31 3 9 40 35 4 69
2022/2023417 58 73 39 27 30 38 1 41 80 0 27 3
2023/2024139 8 5 19 2 18 28 10 9 0 3 23 14
2024/202524 5 19 0 0 0 0 0 0 0 0 0 0
Totale 1.845